Mital Jhaveri: What New Data Reveal About DOACs and Androgen Receptor Inhibitors?
Mital Jhaveri, Clinical Anticoagulation, Heart Failure Pharmacist at NYC HHC Queens Hospital Center, shared on LinkedIn about a recent article by Mary Beth Nierengarten, published in Cancer, adding:
”Drug Interactions in Focus: What New Data Reveal About DOACs and Androgen Receptor Inhibitors
Managing anticoagulation in cancer patients can be complex, particularly due to potential drug-drug interactions that may heighten bleeding or thrombotic risks.
A recent study published in Cancer examined 2,997 patients with prostate cancer who were receiving direct oral anticoagulants (DOACs) in conjunction with androgen receptor pathway inhibitors, including enzalutamide, apalutamide, or abiraterone.
Key findings include:
- No significant increase in thrombosis risk when using enzalutamide or apalutamide alongside DOACs.
- No significant increase in bleeding risk with abiraterone combined with DOACs.
- Real-world evidence supports the safe co-administration of these therapies in appropriately selected patients.
These findings offer valuable reassurance for clinicians making anticoagulation decisions for patients undergoing modern prostate cancer treatments.
They also underscore the importance of considering real-world outcomes alongside theoretical pharmacokinetic concerns.”
Title: New standard of care for patients with asymptomatic brain metastases from melanoma
Author: Mary Beth Nierengarten
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease
-
Sep 3, 2026, 03:51Strengthening Bleeding Disorders Care in New Zealand – WFH
-
Sep 3, 2026, 03:42Nathan Connell: FDA Approves Rusfertide for Polycythemia Vera
-
Sep 3, 2026, 03:28Katrina Snow: Learning More About Sickle Cell Disease This September
-
Sep 3, 2026, 01:19Himanshu Aggarwal: 1 mg/kg/d Thalidomide Non-Inferior to Standard Dose in Transfusion-Dependent Thalassemia
-
Sep 3, 2026, 01:03SHOT Urges Safe Component Matching While NHSBT Appeals for Black Donors
-
Sep 3, 2026, 00:52David Wallace: FDA Approves MIMRYLO to Target Iron Regulation and Reduce Phlebotomy Burden